Navidea Biopharmaceuticals Stock News

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the results of a third-party asset valuation of its Rheumatoid Arthritis (“RA”) diagnostic product candidate. The Company engaged the independent third-party valuation firm, LifeSci Partners

Geode Capital Management LLC lifted its position in shares of Navidea Biopharmaceuticals, Inc. (NYSEAMERICAN:NAVB) by 29.4% during the second quarter, Holdings Channel reports. The institutional investor owned 97,206 shares of the biopharmaceutical companys stock after purchasing an additional 22,064 shares during the period. Geode Capital Management LLCs holdings in Navidea Biopharmaceuticals were worth $177,000 at []

Navidea Biopharmaceuticals, Inc. (NYSEAMERICAN:NAVB) was the recipient of some unusual options trading activity on Monday. Investors purchased 2,246 put options on the stock. This represents an increase of 1,528% compared to the typical daily volume of 138 put options. Separately, Zacks Investment Research raised shares of Navidea Biopharmaceuticals from a sell rating to a hold []

Allred Capital Management LLC lessened its position in shares of Navidea Biopharmaceuticals, Inc. (NYSEAMERICAN:NAVB) by 11.9% during the 3rd quarter, Holdings Channel.com reports. The firm owned 64,988 shares of the biopharmaceutical companys stock after selling 8,800 shares during the quarter. Allred Capital Management LLCs holdings in Navidea Biopharmaceuticals were worth $114,000 as of its most []

Navidea Biopharmaceuticals, Inc. (NAVB) Q3 2021 Results - Earnings Call Transcript

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents an

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents an

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents an

Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q2 2021 Results - Earnings Call Transcript

Navidea (NAVB) delivered earnings and revenue surprises of 0.00% and -56.50%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents an

The stock price of Navidea Biopharmaceuticals Inc (NYSEAMERICAN: NAVB) increased by over 9% pre-market. This is why it happened.

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents an

Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q1 2021 Results - Earnings Call Transcript

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents an